XNCR
USDXencor Inc. Common Stock
Prix en Temps Réel
Graphique des Prix
Métriques Clés
Métriques de Marché
Ouverture
$14.340
Haut
$14.340
Bas
$13.620
Volume
0.91M
Fondamentaux de l'Entreprise
Capitalisation Boursière
972.6M
Industrie
Biotechnologie
Pays
United States
Statistiques de Trading
Volume Moyen
1.15M
Bourse
NGM
Devise
USD
Intervalle sur 52 Semaines
Actualités Connexes
Barclays Upgrades Xencor to Overweight, Raises Price Target to $23
Barclays analyst Etzer Darout upgrades Xencor from Underweight to Overweight and raises the price target from $6 to $23.
RBC Capital Maintains Outperform on Xencor, Raises Price Target to $18
RBC Capital analyst Leonid Timashev maintains Xencor with a Outperform and raises the price target from $15 to $18.
Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma
-- XmAb819 is well-tolerated in heavily pretreated patients with advanced ccRCC -- -- 25% overall response rate (ORR) observed within the target dose range -- -- First dose-expansion cohort has been selected; dose
Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a conference call and webcast on Friday, October 24
Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
-- Management to host webcast and conference call on Friday, October 24, 2025 -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and
Actions Connexes
Restez Informé
Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.